KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Leases (2019 - 2025)

Pacira BioSciences (PCRX) has 7 years of Current Leases data on record, last reported at $9.8 million in Q4 2025.

  • For Q4 2025, Current Leases rose 10.71% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 10.71%, while the annual FY2025 figure was $9.8 million, 10.71% up from the prior year.
  • Current Leases reached $9.8 million in Q4 2025 per PCRX's latest filing, up from $9.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $9.8 million in Q4 2025 and bottomed at $5.5 million in Q1 2021.
  • Average Current Leases over 5 years is $8.4 million, with a median of $8.9 million recorded in 2023.
  • Peak YoY movement for Current Leases: decreased 25.93% in 2021, then soared 45.7% in 2022.
  • A 5-year view of Current Leases shows it stood at $7.9 million in 2021, then grew by 15.59% to $9.1 million in 2022, then fell by 3.51% to $8.8 million in 2023, then increased by 0.98% to $8.9 million in 2024, then rose by 10.71% to $9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $9.8 million in Q4 2025, $9.7 million in Q3 2025, and $9.6 million in Q2 2025.